

神経芽腫委員会

(主) Hishiki T, Matsumoto K, Ohira M, Kamiyo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). *Int J Clin Oncol*. 23:965. 2018. PMID:29700636

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. *Jpn J Clin Oncol*. 48:214. 2018. PMID:29378002

腎腫瘍委員会

(主) Koshinaga T, Takimoto T, Oue T, Okita H, Tanaka Y, Nozaki M, Tsuchiya, Kunihiko, Inoue E, Haruta M, Kaneko Y, Fukuzawa M. Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG). *Pediatr Blood Cancer*. 65:e27056. 2018. PMID:29630767

肝腫瘍委員会

Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, Hiyama E, Czauderna P, Roebuck DJ, Tiao GM. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). *Pediatr Radiol*. 48:536. 2018. PMID:29427028

(主) Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. *N Engl J Med*. 378:2376. 2018. PMID:29924955

リンパ腫委員会

Koga Y, Baba S, Fukano R, Nakamura K, Soejima T, Maeda N, Sunami S, Ueyama J, Mitsui T, Mori T, Osumi T, Sekimizu M, Ohki K, Tanaka F, Kamei M, Fujita N, Mori T, Saito AM, Kada A, Kobayashi R. The Effect of Interim FDG-PET-guided Response-Adapted Therapy in Pediatric Patients with Hodgkin's Lymphoma (HL-14) : Protocol for a Phase II Study. *Acta Med Okayama*. 72:437. 2018. PMID:30140095

Sekimizu M, Fujimoto J, Takimoto T, Tsurusawa M, Horibe K, Sunami S. Phase II Clinical Trial for Newly Diagnosed Children and Adolescents with Localized Lymphoblastic Lymphoma (Japanese Leukemia/Lymphoma Study Group Trial LLB-NHL03) : Study Protocol for Nationwide Multicenter Trial. *Acta Med Okayama*. 72:427. 2018. PMID:30140093

Sekimizu M, Hashimoto H, Mori T, Kobayashi R, Horibe K, Tsurusawa M. Efficacy and safety of administering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. *Pediatr Blood Cancer*. 65:e27068. 2018. PMID:29637700

Fukano R, Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Mori T, Saito AM, Watanabe T, Ohshima K, Fujimoto J, Nakazawa A, Kiyokawa N, Kobayashi R, Horibe K, Tsurusawa M. Clinical Features and Prognosis According to Immunophenotypic Subtypes Including the Early T-Cell Precursor Subtype of T-Lymphoblastic Lymphoma in the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. *J Pediatr Hematol Oncol*. 40:e34. 2018. PMID:28538509

AML 委員会

Matsuo H, Iijima-Yamashita Y, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia. *Pediatr Int*. 60:41. 2018. PMID:29067751

Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Takahashi H, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K. Multiplex fusion gene testing in pediatric acute myeloid leukemia. *Pediatr Int*. 60:47. 2018. PMID:29105243

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S,

Adachi S, Kiyoi H. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. *Int J Hematol.* 107:201. 2018. PMID:29027108

Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM, Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. *Int J Hematol.* 107:586. 2018. PMID:29330746

Yamato G, Shiba N, Yoshida K, Hara Y, Shiraishi Y, Ohki K, Okubo J, Park MJ, Sotomatsu M, Arakawa H, Kiyokawa N, Tomizawa D, Adachi S, Taga T, Horibe K, Miyano S, Ogawa S, Hayashi Y. RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. *Blood.* 131:2266. 2018. PMID:29540347

Tomizawa D, Tanaka S, Hasegawa D, Iwamoto S, Hiramatsu H, Kiyokawa N, Miyachi H, Horibe K, Saito AM, Taga T, Adachi S. Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12). *Jpn J Clin Oncol.* 48:587. 2018. PMID:29889285

Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B, Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, Dworzak M, Sary J, Abrahamsson J, Arad-Cohen N, Czogala M, De Moerloose B, Hasle H, Meshinchi S, van den Heuvel-Eibrink M, Zwaan CM. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. *Blood.* 132:1584. 2018. PMID:30150206

Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, Noura M, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Shiba N, Yamato G, Handa H, Ono Y, Hiramoto N, Ishikawa T, Usuki K, Ishiyama K, Miyawaki S, Itonaga H, Miyazaki Y, Kawamura M, Yamaguchi H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Hayashi Y, Mano H, Miyano S, Kamikubo Y, Ogawa S, Adachi S. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. *Blood Adv.* 2:2879. 2018. PMID:30381403

CML 委員会

Kurosawa H, Tanizawa A, Muramatsu H, Tono C, Watanabe A, Shima H, Ito M, Yuza Y, Hamamoto K, Hotta N, Okada M, Saito AM, Manabe A, Mizutani S, Adachi S, Horibe K, Ishii E, Shimada H. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid

leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Pediatr Blood Cancer*. 65:e27368. 2018. PMID:30084127

HLH/LCH 委員会

Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, Goto H, Kosaka Y, Tsunematsu Y, Imashuku S, Japan LCH Study Group (JLSG) . Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. *Int J Hematol*. 108:192. 2018. PMID:29594922

ALL 委員会

Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, Imamura T, Horibe K, Manabe A. Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. *Jpn J Clin Oncol*. 48:684, 2018. PMID:29860341

児玉祐一, 嶋田博之. フィラデルフィア染色体陽性急性リンパ性白血病 (Ph+ALL) : チロシンキナーゼ阻害薬 (イマチニブやダサチニブなど) 併用化学療法 (保険承認) . *小児内科*. 50:1532. 2018.

CML 委員会・長期フォローアップ委員会共同

Shimada H, Kada A, Shima H, Tono C, Yuza Y, Kurosawa H, Watanabe A, Ito M, Uryu H, Kamibeppu K, Kiyokawa N, Adachi S, Saito M A, Tanizawa A. Rationale and design of a prospective, multicentre, stop tyrosine kinase inhibitor trial of pediatric patients with chronic myeloid leukemia with sustained complete molecular response (STKI-14). *Hiroshima J Med Sci*. 67:7. 2018.